FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655656> ?p ?o ?g. }

• W4385655656 endingPage "e563732e" @default.
• W4385655656 startingPage "e563732e" @default.
• W4385655656 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic sub type of aggressive lymphoma, accounting for approximately 30% of adult non-Hodgkin’s lymphomas (NHL). With the first-line standard regimen R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone), more than half of the patients achieve effective remission. However, 30-40% of patients are still not cured after first-line therapy. The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) is extremely poor. Currently, there is no standardized treatment protocol for this group of patients with relapsed or refractory diffuse large B-cell lymphoma. It is critical to explore effective novel salvage therapy options for this group of patients. Zanubrutinib is a novel irreversible inhibitor of Bruton’s tyrosine kinase (BTK). There are only a few studies on the use of zanubrutinib in patients with RR DLB Aims: This study was designed to evaluate the efficacy and safety of the zanubrutinib combination regimen in patients with RR DLBC Methods:Patients with RR DLBCL who were treated with the combination of zanubrutinib from January 2021 to October 2021 at the Union Hospital of Fujian Medical University were retrospectively collected. all patients received at least 6-8 courses of zanubrutinib combination regimen. The combination regimen included R-CEOP (rituximab, cyclophosphamide, epirubicin, vincristine, prednisone), R2 (rituximab, lenalidomide), R-Gemox (oxaliplatin, gemcitabine), and ZR (cidarabine, rituximab). ctDNA testing was performed in 17 patients. 4 cycles and 8 cycles after PET-CT or CT were used to assess response. Results:There were 17 cases of RR DLBCL with median age of 59 (18-80) years.. 8 (47.1%) patients were women The median follow-up time was 14 months (10-21). At the time of diagnosis, 52.9% (n=9) patients were presented with Ann-Arbor stages III-IV, 76.5% (n=13) were identified with the non-GCB subtype, 29.4% (n=5) patients exhibited double expression, and 17.6% (n=3) patients primary central nervous system lymphoma,70.6% (n=12) had extra-nodal disease,41.2% (n=7) had relapsed disease, and 58.8% (n=10) had refractory diseases. (Table 1). All patients had undetectable mutations after receiving 8 cycles of zanubrutinib combination regimen. The follow-up period ended on October 1, 2022.At the end of treatment, 70.6% (n=12) achieved a CR.the ORR and DCR were 70.6% and 70.6%, respectively. No patient died. The median PFS was16 months (95% CI: 13.2-19.0), the median time to CR of 4 months, and median OS was not estimable.Neutropenia (n=11, 64.7%) and were the most common grade 3/4 adverse events. The most non-hematologic adverse events were fatigue (n=2,11.8%), nausea and vomiting (n=8, 47.1%).No death due to adverse reactions occurred Summary/Conclusion:Zanubrutinib combination therapy has a high remission rate in RR DLBCL. Serious adverse reactions were less frequent and zanubrutinib treatment was tolerable during in patients with RRDLBCL.Keywords: Diffuse large B cell lymphoma, DLBCL, B cell lymphoma" @default.
• W4385655656 created "2023-08-09" @default.
• W4385655656 creator A5032854816 @default.
• W4385655656 creator A5053945199 @default.
• W4385655656 creator A5057855713 @default.
• W4385655656 creator A5063038462 @default.
• W4385655656 creator A5089163403 @default.
• W4385655656 date "2023-08-01" @default.
• W4385655656 modified "2023-09-27" @default.
• W4385655656 title "PB2311: EFFICACY EVALUATION AND SAFETY ANALYSIS OF ZANUBRUTINI B COMBINED WITH CHEMOTHERAPY FOR 17 CASES OF RELAPSED REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA" @default.
• W4385655656 doi "https://doi.org/10.1097/01.hs9.0000975968.56373.2e" @default.
• W4385655656 hasPublicationYear "2023" @default.
• W4385655656 type Work @default.
• W4385655656 citedByCount "0" @default.
• W4385655656 crossrefType "journal-article" @default.
• W4385655656 hasAuthorship W4385655656A5032854816 @default.
• W4385655656 hasAuthorship W4385655656A5053945199 @default.
• W4385655656 hasAuthorship W4385655656A5057855713 @default.
• W4385655656 hasAuthorship W4385655656A5063038462 @default.
• W4385655656 hasAuthorship W4385655656A5089163403 @default.
• W4385655656 hasBestOaLocation W43856556561 @default.
• W4385655656 hasConcept C126322002 @default.
• W4385655656 hasConcept C143998085 @default.
• W4385655656 hasConcept C2776694085 @default.
• W4385655656 hasConcept C2776755627 @default.
• W4385655656 hasConcept C2777938653 @default.
• W4385655656 hasConcept C2778461978 @default.
• W4385655656 hasConcept C2778559949 @default.
• W4385655656 hasConcept C2778720950 @default.
• W4385655656 hasConcept C2779338263 @default.
• W4385655656 hasConcept C2779429289 @default.
• W4385655656 hasConcept C2779878957 @default.
• W4385655656 hasConcept C2780653079 @default.
• W4385655656 hasConcept C2780775027 @default.
• W4385655656 hasConcept C2781413609 @default.
• W4385655656 hasConcept C71924100 @default.
• W4385655656 hasConcept C90924648 @default.
• W4385655656 hasConceptScore W4385655656C126322002 @default.
• W4385655656 hasConceptScore W4385655656C143998085 @default.
• W4385655656 hasConceptScore W4385655656C2776694085 @default.
• W4385655656 hasConceptScore W4385655656C2776755627 @default.
• W4385655656 hasConceptScore W4385655656C2777938653 @default.
• W4385655656 hasConceptScore W4385655656C2778461978 @default.
• W4385655656 hasConceptScore W4385655656C2778559949 @default.
• W4385655656 hasConceptScore W4385655656C2778720950 @default.
• W4385655656 hasConceptScore W4385655656C2779338263 @default.
• W4385655656 hasConceptScore W4385655656C2779429289 @default.
• W4385655656 hasConceptScore W4385655656C2779878957 @default.
• W4385655656 hasConceptScore W4385655656C2780653079 @default.
• W4385655656 hasConceptScore W4385655656C2780775027 @default.
• W4385655656 hasConceptScore W4385655656C2781413609 @default.
• W4385655656 hasConceptScore W4385655656C71924100 @default.
• W4385655656 hasConceptScore W4385655656C90924648 @default.
• W4385655656 hasIssue "S3" @default.
• W4385655656 hasLocation W43856556561 @default.
• W4385655656 hasLocation W43856556562 @default.
• W4385655656 hasOpenAccess W4385655656 @default.
• W4385655656 hasPrimaryLocation W43856556561 @default.
• W4385655656 hasRelatedWork W2023162095 @default.
• W4385655656 hasRelatedWork W2056874874 @default.
• W4385655656 hasRelatedWork W2132500976 @default.
• W4385655656 hasRelatedWork W2213920779 @default.
• W4385655656 hasRelatedWork W2467938374 @default.
• W4385655656 hasRelatedWork W2895858698 @default.
• W4385655656 hasRelatedWork W2935716814 @default.
• W4385655656 hasRelatedWork W3212185513 @default.
• W4385655656 hasRelatedWork W4206209534 @default.
• W4385655656 hasRelatedWork W4250500771 @default.
• W4385655656 hasVolume "7" @default.
• W4385655656 isParatext "false" @default.
• W4385655656 isRetracted "false" @default.
• W4385655656 workType "article" @default.